Target Name: RBM27
NCBI ID: G54439
Review Report on RBM27 Target / Biomarker Content of Review Report on RBM27 Target / Biomarker
RBM27
Other Name(s): RNA-binding motif protein 27 | RNA binding motif protein 27 | RBM27_HUMAN | RNA-binding protein 27 | Psc1 | ZC3H20 | acidic rich RS domain containing 1 | ARRS1 | ZC3H18 | KIAA1311

RBM27: A Promising Drug Target / Biomarker

RBM27 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidney. It is a member of the superfamily of G-protein-coupled receptors (GPCRs), which are a family of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and hormone regulation.

The discovery and characterization of RBM27

RBM27 was first identified as a gene encoding a protein with 27 amino acid residues using gene expression arrays and subsequent cloning of the cDNA. The protein is composed of a single exon that is predominantly expressed in the brain, with lower levels of expression in the heart, liver, and kidney.

To determine the function of RBM27, researchers used a variety of techniques, including in vitro and in vivo experiments, to study its effects on cellular signaling pathways. These studies revealed that RBM27 is involved in the regulation of neurotransmitter signaling, specifically in the signaling pathway involving neurotransmitter GABA.

In addition to its role in neurotransmitter signaling, RBM27 has also been shown to play a key role in the regulation of ion channels, which are responsible for the flow of electrical current through the cell membrane. This is important for the function of many different cellular processes, including muscle contractions and neurotransmitter release.

The potential clinical applications of RBM27

The discovery of RBM27 as a drug target or biomarker has significant implications for the development of new treatments for a variety of neurological and psychiatric disorders.

In addition to its role in neurotransmitter signaling, RBM27 has also been shown to play a key role in the regulation of ion channels, which are important for many different cellular processes. This suggests that RBM27 may be a useful target for interventions aimed at modulating ion channels, such as those involved in epilepsy and other neurological disorders.

In addition to its potential as a drug target, RBM27 has also been shown to be a potential biomarker for a variety of neurological disorders. For example, studies have shown that RBM27 levels are elevated in individuals with certain forms of dementia, which suggests that it may be a useful biomarker for the diagnosis and progression of these disorders.

The development of small molecules that can modulate RBM27 activity could have a significant impact on the treatment of a wide range of neurological and psychiatric disorders. However, the development of new drugs that can specifically modulate RBM27 activity will require further research to fully understand its role in cellular signaling and its potential as a drug target.

Conclusion

RBM27 is a protein that is involved in a wide range of cellular signaling pathways, including those involved in neurotransmitter signaling and ion channel regulation. Its potential as a drug target or biomarker has significant implications for the development of new treatments for a variety of neurological and psychiatric disorders. Further research is needed to fully understand its role in cellular signaling and its potential as a therapeutic intervention.

Protein Name: RNA Binding Motif Protein 27

The "RBM27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3 | RCSD1 | RCVRN | RD3 | RD3L | RDH10 | RDH11 | RDH12 | RDH13 | RDH14 | RDH16 | RDH5 | RDH8 | RDM1 | RDUR | RDX | RDXP2 | Reactive oxygen species (ROS) | REC114 | REC8 | RECK | RECQL | RECQL4